Korean J Gastroenterol.  2014 Jan;63(1):3-10. 10.4166/kjg.2014.63.1.3.

Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease

Affiliations
  • 1Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. jh2002@dau.ac.kr

Abstract

The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.

Keyword

Chemoprevention; Inflammatory bowel diseases; Colorectal neoplasms

MeSH Terms

Anti-Inflammatory Agents/therapeutic use
Chemoprevention
Colorectal Neoplasms/*complications/*prevention & control
Folic Acid/therapeutic use
Immunosuppressive Agents/therapeutic use
Inflammatory Bowel Diseases/*complications/drug therapy
Mesalamine/therapeutic use
Ursodeoxycholic Acid/therapeutic use
Anti-Inflammatory Agents
Folic Acid
Immunosuppressive Agents
Mesalamine
Ursodeoxycholic Acid
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr